|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...3839404142434445464748...6768» |
- | Trial completion: Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=42, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed
- bortezomib / Generic mfg., prednisone / Generic mfg., melphalan / Generic mfg.
Trial completion: VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P3, N=0, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed No longer recruiting --> Completed
- || ATryn (antithrombin) / LFB SA, Knight Therap
Trial completion, Surgery: Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery (clinicaltrials.gov) - Feb 22, 2014
P3, N=18, Completed, Sponsor: rEVO Biologics
No longer recruiting --> Completed Recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi
Trial completion, Combination therapy: Campath-1H + FK506 and Methylprednisolone for GVHD (clinicaltrials.gov) - Feb 22, 2014
P2, N=34, Completed, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- |||| zoledronic acid / Generic mfg.
Trial completion: A Multiple Myeloma Trial in Patients With Bone Metastases (clinicaltrials.gov) - Feb 22, 2014
P4, N=179, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed No longer recruiting --> Completed
- |||| Promacta (eltrombopag) / Novartis
Trial completion: SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 22, 2014
P2, N=99, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed No longer recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Combination therapy, Epigenetic controller, Metastases: MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 22, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P3, N=225, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | mycophenolate mofetil / Generic mfg.
Trial completion, Metastases: Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || BeneFix (nonacog alfa) / Pfizer
Trial completion: Study Evaluating rFIX; BeneFIX (clinicaltrials.gov) - Feb 22, 2014
P3, N=23, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant (clinicaltrials.gov) - Feb 22, 2014
P2, N=10, Completed, Sponsor: University of Arkansas
No longer recruiting --> Completed Recruiting --> Completed
- | Trial completion, Metastases: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | dexamethasone / Generic mfg., melphalan / Generic mfg., thalidomide / Generic mfg.
Trial completion, IO biomarker: Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | dexamethasone / Generic mfg., thalidomide / Generic mfg.
Trial completion, Combination therapy, Post-transplantation: Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=190, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| melphalan / Generic mfg.
Trial completion: D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P3, N=500, Completed, Sponsor: University of Arkansas
No longer recruiting --> Completed No longer recruiting --> Completed
- | thalidomide / Generic mfg.
Trial completion: Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: University of Arkansas
No longer recruiting --> Completed No longer recruiting --> Completed
- | thalidomide / Generic mfg.
Trial completion, Combination therapy, Post-transplantation: DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse (clinicaltrials.gov) - Feb 22, 2014
P2, N=180, Completed, Sponsor: University of Arkansas
No longer recruiting --> Completed No longer recruiting --> Completed
- | bortezomib / Generic mfg., thalidomide / Generic mfg.
Trial completion: Study of Combination PS-341 and Thalidomide in Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P1, N=86, Completed, Sponsor: University of Arkansas
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- | Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion: Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P2, N=50, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Recruiting --> Completed
- | voriconazole / Generic mfg.
Trial completion: Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure (clinicaltrials.gov) - Feb 22, 2014
P1, N=5, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Genasense (oblimersen) / Genta
Trial completion: Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=58, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- | alvocidib (DSP-2033) / Sumitomo Pharma, Rituxan (rituximab) / Roche
Trial completion: Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P1, N=37, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- |||| lenalidomide / Generic mfg.
Trial completion: A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P2, N=100, Completed, Sponsor: Celgene Corporation
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg.
Trial completion: PS-341 (VELCADE (clinicaltrials.gov) - Feb 22, 2014
P3, N=620, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- | alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P2, N=35, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | bortezomib / Generic mfg.
Trial completion: Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Feb 22, 2014
P2, N=27, Completed, Sponsor: NCIC Clinical Trials Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- melphalan / Generic mfg.
Trial completion: Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=0, Completed, Sponsor: Poniard Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || thalidomide / Generic mfg.
Trial completion: Thalidomide for Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P3, N=27, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Terminated --> Completed
- ||||||| thalidomide / Generic mfg.
Trial completion: Thalidomide-Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=83, Completed, Sponsor: M.D. Anderson Cancer Center
Terminated --> Completed Terminated --> Completed
- |||| zoledronic acid / Generic mfg.
Trial completion, HEOR: Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions (clinicaltrials.gov) - Feb 22, 2014
P4, N=500, Completed, Sponsor: Novartis
Terminated --> Completed No longer recruiting --> Completed
- | Panzem (2-methoxyestradiol) / CASI
Trial completion, Metastases: 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi
Trial completion: Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=51, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (clinicaltrials.gov) - Feb 22, 2014
P1, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- melphalan / Generic mfg.
Enrollment change: Agaricus Blazei Murill in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 21, 2014
P2, N=39, Completed, Sponsor: Ullevaal University Hospital
No longer recruiting --> Completed N=30 --> 39
- melphalan / Generic mfg.
Trial completion: Agaricus Blazei Murill in Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 21, 2014
P2, N=39, Completed, Sponsor: Ullevaal University Hospital
N=30 --> 39 Recruiting --> Completed
- busulfan / Generic mfg.
Trial initiation date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Feb 20, 2014
P0, N=30, Recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Completed Initiation date: Nov 2013 --> Mar 2014
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Metastases: Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (clinicaltrials.gov) - Feb 20, 2014
P1, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2013 --> Mar 2014 N=118 --> 15
- olaptesed pegol (NOX-A12) / TME Pharma
Enrollment closed, Combination therapy: NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2014
P2a, N=29, Active, not recruiting, Sponsor: Noxxon Pharma AG
N=118 --> 15 Recruiting --> Active, not recruiting
- | peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | clarithromycin / Generic mfg.
Trial completion: Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | peripheral blood stem cell transplantation / National Cancer Institute
Trial completion: Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Feb 19, 2014
P2, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | melphalan / Generic mfg.
Trial completion: High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Temple University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Xyntha (moroctocog alfa) / Pfizer
Enrollment open: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Feb 19, 2014
P4, N=200, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Trial completion: Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: California Cancer Consortium
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- Neovastat (AE 941) / AEterna Zentaris
Trial completion: AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: AEterna Zentaris
No longer recruiting --> Completed Active, not recruiting --> Completed
- | dexamethasone / Generic mfg., isotretinoin / Generic mfg.
Trial completion: Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=17, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed